

# PATHKINEX UPDATE



## PathKinex™ 2025 Year in Review

*Written by Heidi Doden, Microbiologist IV at Microbial Discovery Group*

As the year comes to a close, we're reflecting on the innovative progress we've made with the PathKinex™ program, beginning with the update to 21,000 isolates in the PathKinex™ pathogen libraries and ending with a new, interactive

PathKinex™ report format. Throughout the year, we shared data on how our ECL products were able to inhibit over 90% of *E. coli*, *Clostridium*, and *Salmonella* tested; watched timelapse videos of our strains in action; and examined how ProVent® ECL performed during *in vivo E. coli* challenge models.

On a higher level, we focused on the importance of coinfections in the livestock industry. This year's PathKinex™ updates highlighted our ECL products' ability to inhibit multiple pathogen species, discussed multi-species coinfections involving coccidia and *C. perfringens*, and showcased insights from PathKinex™ surveillance on highly pathogenic avian influenza in dairy cattle.

This year also brought themes of multiple modes of action, revealing new *in vitro* assays for inhibition of pathogen biofilm formation and quorum-sensing, as well as the impact of our ECL products on the immune response.

Beyond PathKinex™, we investigated the environmental benefits of *Bacillus*, ranging from their ability to reduce noxious gas emissions on the farm to improving biogas production in methane capture systems.

To further explore these and more achievements from 2025, take a look at our PathKinex™ Year in Review!

## 2025 YEAR IN REVIEW



**Thanks for following along with PathKinex™ this year. We are excited to keep pursuing microbial solutions for animal health in 2026!**



[Click Here to Unsubscribe](#)